The Manufacturers Life Insurance Company Takes Position in The Cooper Companies, Inc. $COO

Posted by George Bondi on Aug 26th, 2026

The Manufacturers Life Insurance Company acquired a new position in shares of The Cooper Companies, Inc. (NASDAQ:COO – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 964,007 shares of the medical device company’s stock, valued at approximately $69,129,000.

Other hedge funds have also modified their holdings of the company. Avalon Trust Co acquired a new position in Cooper Companies during the second quarter worth approximately $25,000. Root Financial Partners LLC raised its position in shares of Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after buying an additional 162 shares during the period. SJS Investment Consulting Inc. boosted its holdings in Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 187 shares during the last quarter. Elevation Wealth Partners LLC boosted its holdings in Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 375 shares during the last quarter. Finally, J.Safra Asset Management Corp purchased a new stake in Cooper Companies during the second quarter valued at about $32,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

Positive Sentiment: Traders purchased 4,056 call options on COO, roughly 411% above the typical daily volume of 794 contracts. This points to increased speculative bullish interest, although options activity alone does not guarantee a sustained stock advance.
Neutral Sentiment: The latest short-interest report lists zero shares sold short and a 0.0-day short-interest ratio, but it also describes the change as “NaN” from a prior total of zero. The figures appear inconsistent and provide little useful information about investor positioning. Short Interest Report
Negative Sentiment: COO’s valuation remains demanding, with a reported P/E ratio near 62. That can make the shares more sensitive to profit-taking or a lack of fresh positive catalysts, even though the company recently exceeded quarterly earnings and revenue expectations and reported year-over-year revenue growth.

Cooper Companies Stock Performance

Shares of COO stock opened at $73.04 on Wednesday. The stock has a market capitalization of $14.24 billion, a price-to-earnings ratio of 61.90, a PEG ratio of 1.98 and a beta of 0.83. The Cooper Companies, Inc. has a one year low of $58.89 and a one year high of $89.83. The company’s 50-day simple moving average is $72.20 and its 200-day simple moving average is $71.01. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27.

Cooper Companies (NASDAQ:COO – Get Free Report) last announced its quarterly earnings data on Thursday, June 4th. The medical device company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.11. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company earned $0.96 earnings per share. Cooper Companies’s quarterly revenue was up 7.9% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Equities analysts anticipate that The Cooper Companies, Inc. will post 4.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on COO shares. UBS Group assumed coverage on Cooper Companies in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $75.00 price objective on the stock. Stifel Nicolaus reduced their target price on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, June 5th. The Goldman Sachs Group set a $61.00 price target on Cooper Companies in a report on Wednesday, May 27th. Wall Street Zen raised Cooper Companies from a “hold” rating to a “buy” rating in a research report on Sunday, June 21st. Finally, Piper Sandler set a $86.00 target price on Cooper Companies and gave the company an “overweight” rating in a report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $81.64.

Check Out Our Latest Analysis on COO

Cooper Companies Profile

(Free Report)

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.